Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.
JAMA oncology（2023）
摘要
ClinicalTrials.gov Identifiers: NCT02367781, NCT02657434, and NCT02366143.
更多查看译文
关键词
atezolizumab,cell lung cancer,non–small cell lung cancer,lung cancer,immune-related
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要